The Alzheimer’s Association and the Michael J. Fox Foundation launched a bridge funding program supporting 18 neurodegenerative research projects and early-career scientists. The initiative is designed to sustain work during funding transitions, preserving momentum for preclinical and translational studies. For researchers, bridge programs reduce interruption risk and can be especially important for early-stage teams that have cleared initial scientific hurdles but need time to generate stronger datasets. For the sector, the funding step signals continued emphasis on pipeline replenishment across neurodegeneration beyond a single disease platform. The provided record does not detail the specific project areas beyond the general neurodegenerative focus, but the portfolio breadth supports the program’s role as a continuity mechanism for the field.